Alleviant ALLAY-HFrEF Study
At a glance
Conditions
NCT06812533
Where you'd take part
This study runs at 68 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Alfred Hospital
Melbourne, Victoria, Australiano site contact published
Recruiting
Ascension Sacred Heart
Pensacola, Floridano site contact published
Recruiting
Atlanta VA Health Care System
Decatur, Georgiano site contact published
Recruiting
Austin Heart
Austin, Texasno site contact published
Recruiting
AZ Sint Jan Brugge
Bruges, Belgiumno site contact published
Recruiting
Baylor Scott & White - Temple
Temple, Texasno site contact published
Recruiting
Baylor Scott & White Research Institute
Plano, Texasno site contact published
Recruiting
Boston Medical Center
Boston, Massachusettsno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Gregg Stone · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai
- James Udelson · PRINCIPAL_INVESTIGATOR · Tufts Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Composite Primary Endpoint12-Month
The primary endpoint is a composite of all-cause mortality or cardiac transplantation or permanent left ventricular assist device (LVAD) and heart failure events.